Federal Budget is a Step in the Right Direction Says Rx&D

OTTAWA, June 6, 2011 /CNW/ - The following is a statement by Russell Williams, President of Canada's Research-based Pharmaceutical Companies (Rx&D) on the Federal Budget presented by Finance Minister Jim Flaherty on June 6, 2011 and on the Speech from the Throne of June 3, 2011.

"As the industry that discovers and develops the medicines and vaccines that improve and save lives, we welcome the direction taken in the budget and the throne speech to spark innovation and promote health and research.

"We commend the Government of Canada's commitment to negotiate the Comprehensive Economic and Trade Agreement (CETA) with the European Union by 2012 which has the potential to create jobs and investment in life sciences and the knowledge economy. CETA matters. It is crucial that Canada improve its Intellectual Property Regime to levels already enjoyed by the EU and other major trading partners.

"We applaud the Harper government's Shared Vision for Perimeter Security and Economic Competitiveness with the U.S., especially the work of the Regulatory Cooperation Council to harmonize regulations and reduce unnecessary red tape.

"We are also encouraged by the government's support of up to $100 million to help establish a Canada Brain Research Fund which is designed to put Canada at the forefront of scientific discovery to improve the health and quality of life for Canadians who suffer from brain disorders.

"We support measures such as providing an additional $65 million for Genome Canada to continue its ground breaking work as well as $37 million per year to support the three federal research granting councils along with the creation of 10 new Canada Excellence Research Chairs.

"We welcome the additional support for community based palliative care which is welcome and necessary for patients and families who need care and compassion at end of life.

"We cannot overstate the urgent need to take action to preserve life sciences research and attract more jobs and investment in a fiercely competitive global market.

"We look forward to working with all levels of government to deliver a scientific innovation and knowledge agenda that will result in better health and greater prosperity."

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.



SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX

For further information:

Christine Choury
Media Relations
Telephone: 613-236-0455
E-mail: cchoury@canadapharma.org

Organization Profile

CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890